Kevin Tang - Dec 5, 2024 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Director
Signature
Kevin Tang
Stock symbol
AUPH
Transactions as of
Dec 5, 2024
Transactions value $
$10,822,000
Form type
4
Date filed
12/9/2024, 04:52 PM
Previous filing
Sep 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Shares Purchase $2.67M +300K +4.15% $8.91 7.53M Dec 5, 2024 By LP F1, F2
transaction AUPH Common Shares Purchase $3.6M +400K +5.31% $9.01 7.93M Dec 6, 2024 By LP F2, F3
transaction AUPH Common Shares Purchase $4.55M +500K +6.31% $9.09 8.43M Dec 9, 2024 By LP F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $8.74 to $8.99. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4.
F2 Tang Capital Partners, LP ("TCP") beneficially owns 7,929,500 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCP III.
F3 These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.15.
F4 These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.19.